• Advances in the Understanding of Etiology (I)
• 30 min
  1. Infection and autoimmunity: a two-way relationship

  • Dr. Ricard Cervera
• 35 min
  2. Autoimmunity and atherosclerosis

  • Prof. Johan Frostegard
• 47 min
  3. Endothelium and autoimmunity

  • Prof. Pier Luigi Meroni
• Advances in the Understanding of Etiology (II)
• 22 min
  4. Prolactin has a pathogenic role in systemic lupus erythematosus

  • Prof. Luis Jara-Quezada
• 44 min
  5. Sjögren's syndrome: current knowledge and future prospects

  • Prof. Athanasios G. Tzioufas
• 51 min
  6. Genetic and environmental triggers of autoimmune thyroid diseases

  • Prof. Yaron Tomer
• Advances in Pathogenesis and Clinical Manifestation
• 38 min
  7. The catastrophic antiphospholipid syndrome and the microangiopathic antiphospholipid syndrome

  • Prof. Ronald Asherson
• 20 min
  8. Pathogenic mechanisms of autoantibodies: circulating and local antibodies that form immune complexes

  • Dr. Luís Eduardo Coelho Andrade
• 34 min
  9. Pathogenic mechanisms of autoantibodies: antibodies to intracellular and membrane-bound antigens

  • Dr. Luís Eduardo Coelho Andrade
• 43 min
  10. What causes primary biliary cholangitis?

  • Dr. M. Eric Gershwin
• 30 min
  11. Capillaroscopy in autoimmune rheumatic diseases

  • Prof. Maurizio Cutolo
• Advances in Diagnostic Methodologies (I)
• 26 min
  12. The past, present & future of ANA testing: history and challenges of ANA

  • Prof. Marvin J. Fritzler
• 33 min
  13. The past, present & future of ANA testing: changing bandwidth and future of ANA

  • Prof. Marvin J. Fritzler
• 36 min
  14. Diagnostic methods in autoimmunity

  • Mr. Steven Binder
• 24 min
  15. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 1

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 28 min
  16. Systemic lupus erythematosus: novel aspects of pathogenesis and treatment 2

  • Prof. Chaim Putterman
  • Dr. Noa Schwartz
• 48 min
  17. Novel aspects of systemic sclerosis

  • Prof. Gabriele Valentini
• Advances in Diagnostic Methodologies (II)
• 46 min
  18. An update on the multiple faces of celiac disease

  • Prof. Aaron Lerner
• 23 min
  19. Protective autoantibodies

  • Prof. Elias Toubi
• 32 min
  20. CD44 genetic deletion enhances and CD44 antibody targeting attenuates autoimmune inflammation

  • Prof. David Naor
• 44 min
  21. Rheumatic fever: a model of a post-infectious autoimmune disease

  • Prof. Jorge Kalil
• Treatments of autoimmune diseases
• 38 min
  22. Intravenous immunoglobulins: clinical evidence

  • Prof. Shaye Kivity
• Latest Developments in the Field
• 26 min
  23. Adjuvants and autoimmunity

  • Dr. Eitan Israeli
• 46 min
  24. Antiphospholipid syndrome (APS): from pathogenesis to treatment

  • Prof. Roger Levy
• 24 min
  25. Vitamin D and autoimmunity

  • Dr. Shir Azrielant
• 28 min
  26. Pregnancy in rheumatic diseases

  • Prof. Pier Luigi Meroni
• Archived Lectures *These may not cover the latest advances in the field
• 47 min
  27. Pathogenic mechanisms of autoantibodies

  • Prof. Cees Kallenberg
• 41 min
  28. B lymphocytes on the frontline of autoimmunity

  • Prof. Pierre Youinou
• 42 min
  29. Apoptotic cell clearance deficiency

  • Prof. Martin Herrmann
• 34 min
  30. Auto-antibodies as predictors of autoimmune disease

  • Dr. Nicola Bizzaro
• 46 min
  31. Innate immunity and natural autoantibodies

  • Prof. Luc Mouthon
• 45 min
  32. Accelerated atherosclerosis in autoimmune rheumatic disease

  • Dr. Andrea Doria
• 47 min
  33. Pregnancy in autoimmune rheumatic diseases

  • Prof. Angela Tincani
• 42 min
  34. Pulmonary hypertension in the connective tissue disease pathogenesis, clinical features and therapeutic options in 2006

  • Prof. Ronald Asherson
• 39 min
  35. Use of algorithms for high quality diagnostics and handling of patients with autoimmune rheumatic diseases

  • Dr. Allan Wiik
• 24 min
  36. Immunologic mechanisms in systemic lupus erythematosus

  • Prof. Kok-Yong Fong
• 23 min
  37. Osteoimmunology

  • Prof. João Eurico Fonseca
  • Ms. Joana Caetano-Lopes
• 43 min
  38. ANCA-associated systemic vasculitides

  • Prof. Loic Guillevin
• 23 min
  39. The common origin for diverse autoimmune diseases

  • Prof. Juan-Manuel Anaya
• 76 min
  40. Anti-cytokine therapy in rheumatoid arthritis

  • Prof. Piercarlo Sarzi-Puttini
• 40 min
  41. Sjogren's syndrome: autoimmune epithelitis

  • Prof. Haralampos Moutsopoulos
• 31 min
  42. Vitamin D and autoimmunity

  • Dr. Howard Amital
• 25 min
  43. Intravenous immunoglobulins: myth and reality

  • Prof. Zera Tellier

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. History: fetal loss and LAC
4. The use of anti-cardiolipin antigen
5. GPL and past obstetric history
6. International lupus congress NY 2002
7. The primary antiphospholipid syndrome (pAPS)
8. Causes of thromboses in SLE
9. Congenital thrombophilias
10. APS classification criteria (1)
11. Sapporo 1998 conference
12. APS classification criteria (2)
13. APS classification criteria (3)
14. LACs
15. Anti-cardiolipin test (aCL)
16. Autoimmunity
17. Lupus and APS
18. APS is related to LAC, aCL, anti-beta 2GP-I
19. Frequency of aPL
20. Systemic APS
21. The Euro PL study
22. Thrombotic microangiopathy (MAPS)
23. Clinical presentations of APS
24. The Lucio phenomenon
25. Ginsberg study, blood 1992
26. Targets: action
27. Pathogenic mechanisms
28. Pathogenesis data from animal models
29. Passive and active transfer of APS
30. Pathogenesis of obstetric APS (1)
31. Pathogenesis of obstetric APS (2)
32. CNS involvement in APS
33. Snnedon's syndrome
34. Neural injury pathogenesis in APS animal models
35. Cardiopulmonary clinical presentation
36. Importance of BP control in APS
37. Impact of hypertension and hyperhomocysteinemia
38. Management of APS
39. Asymptomatic aPL
40. Thrombosis treatment
41. INR recommendations
42. The importance of INR monitoring
43. APS patients should maintain a monotonous diet
44. Thrombocytopenia
45. Obstetric management of APS
46. Pregnancy: thrombosis and aPL
47. Results from hospital university Pedro Ernesto
48. Advantages and disadvantages of heparin
49. Pregnancy and coumadin; clinical study (1)
50. Pregnancy and coumadin; clinical study (2)
51. Pregnancy and coumadin; clinical study (3)
52. APS and preeclampsia
53. HCQ in SLE pregnancy: clinical study
54. Thrombocytopenia during pregnancy
55. Catastrophic APS
56. Alternative therapies
57. Thromboses prevention
58. Second hit
59. Triggering factors
60. Case study: 29 year old woman with pAPS
61. Vaccination as an APS triggering factor
62. Thromboembolism and antipsychotics
63. Lung adenocarcinoma and thrombosis (1)
64. Lung adenocarcinoma and thrombosis (2)
65. The future of APS treatment
66. APS: messages
67. There is still a lot to learn
68. Ethical issues
69. Acknowledgements
70. The 14'th international APS congress

Topics Covered

• History: fetal loss and LAC
• The use of anti-cardiolipin antigen
• GPL and past obstetric history
• The primary antiphospholipid syndrome (pAPS)
• Causes of thromboses in SLE
• Congenital thrombophilias
• APS classification criteria
• Anti-cardiolipin test (aCL)
• Autoimmunity
• Lupus and APS
• Thrombotic microangiopathy (MAPS)
• The Lucio phenomenon
• Pathogenesis
• CNS involvement in APS
• Snnedon's syndrome
• Neural injury pathogenesis in APS animal models
• Management of APS
• Asymptomatic aPL
• Thrombosis treatment
• INR recommendations
• Thrombocytopenia
• Obstetric management of APS
• Advantages and disadvantages of heparin
• Pregnancy and coumadin; clinical study
• APS and preeclampsia
• HCQ in SLE pregnancy: clinical study
• Thrombocytopenia during pregnancy
• Catastrophic APS
• Alternative therapies
• Vaccination as an APS triggering factor
• Thromboembolism and antipsychotics
• Lung adenocarcinoma and thrombosis
• The future of APS treatment
• Ethical issues

Links

Series:

• Autoimmunity

Categories:

• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on February 9, 2010

Financial Disclosures

• Prof. Roger Levy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.